YANG Yunyun, CAI Lu, WANG Xuebin, et al. Establishment of Reversed Phase High Performance Liquid Chromatography Method for Plasma Teicoplanin Concentration[J]. 2020,20(9):1041-1043.
YANG Yunyun, CAI Lu, WANG Xuebin, et al. Establishment of Reversed Phase High Performance Liquid Chromatography Method for Plasma Teicoplanin Concentration[J]. 2020,20(9):1041-1043. DOI: 10.14009/j.issn.1672-2124.2020.09.004.
血浆替考拉宁浓度的反相高效液相色谱分析方法的建立
摘要
目的:建立反相高效液相色谱法(reversed phase high performance liquid chromatography
RP-HPLC)测定人血浆中替考拉宁的浓度。方法:采用Waters C
18
色谱柱(150 mm×4.6 mm
5μm)
流动相为0.02 mol/L的NaH
2
PO
4
(pH=2.50)-乙腈(V∶V=74.5∶25.5)
内标物为对羟基苯甲酸甲酯
流速为1.0 ml/min
检测波长为240 nm
进样体积为0.020 ml
柱温为35℃。结果:在上述色谱条件下
替考拉宁和内标的分离度均良好(R
>
1.5)
替考拉宁保留时间约9 min
内标物保留时间约为11 min
替考拉宁在3.125~100μg/ml(r=99.96%
n=6)范围内线性关系良好;定量下限为3.125μg/ml时
信噪比(S/N)=18.5
批内和批间的准确度和精密度均符合要求。结论:本研究方法适合测定人血浆中替考拉宁的浓度
为替考拉宁的个体化用药提供指导。
Abstract
OBJECTIVE: To establish a method of reversed phase high performance liquid chromatography (RPHPLC) for the determination of teicoplanin in human plasma. METHODS: Waters C
18
column (150 mm × 4. 6 mm
5 μm) was used
the mobile phase was 0. 02 mol/L of NaH
2
PO
4
(pH = 2. 50)-acetonitrile (V ∶V = 74. 5 ∶25. 5)
the internal standard substance was methyl parahydroxybenzoats
with the flow rate was 1. 0 ml/min
the detection wavelength was 240 nm
the injection volume was 0. 020 ml and the column temperature was 35 ℃ . RESULTS: Under the above chromatographic conditions
both the resolutions of teicoplanin and internal standard substance were good (R
>
1. 5)
the retention time of teicoplanin was about 9 min and the retention time of internal standard substance was about 11 min
the linear relationship was good in the range of 3. 125-100 μg/ml (r = 99. 96%
n = 6); when the lower limit of quantification was 3. 125 μg/ml
the signal-to-noise ratio (S/N) was 18. 5
both the accuracy and precision of intra-batch and inter-batch meet the requirements. CONCLUSIONS: This research method is suitable for determining the concentration of teicoplanin in human plasma and provides guidance for the individualized medication of teicoplanin.